4-甲基-2-戊烯酰胺 | 61892-67-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-甲基-2-戊烯酰胺
• 英文名称: trans-4-methyl-pent-2-enoic acid amide
• 英文别名: trans-4-Methyl-pent-2-ensaeure-amid；(E)-4-methylpent-2-enamide
• CAS: 61892-67-9
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: MXEMAOPYTXHVEM-ONEGZZNKSA-N

物化性质

• 熔点：
  83-86 °C
• 沸点：
  233.0±13.0 °C(Predicted)
• 密度：
  0.924±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-甲基-2-戊烯酰胺 在 盐酸 、 甲酸 、 二异丁基氢化铝 、 四乙基氟化铵水合物 、 potassium carbonate 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 异丙醇 、 甲苯 为溶剂， 反应 34.33h， 生成 (S)-2-[(2E,4E)-2,4-hexadienoyl]-7-(2-{5-methyl-2-[(1E)-3-methylbut-1-en-1-yl]oxazol-4-yl}ethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid tert-butylammonium salt
  参考文献：
  名称：

  Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: Peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition

  摘要：

  A novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and (S)-2-[(2E,4E)- hexadienoyl]-7-(2-(5-methyl-2-[( 1E)-5-methylhexen-1-yl]oxazol-4-yl]ethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (14i) was identified as a potent human peroxisome proliferator-activated receptor gamma (PPAR gamma) selective agonist (EC(50) = 0.03 mu M) and human protein-tyrosine phosphatase 1B (PTP-1B) inhibitor (IC(50) = 1.18 mu M). C(max) after oral administration of 14i at 10 mg/kg was 2.2 mu g/ml (4.5 mu M) in male SD rats. Repeated administration of 14i and rosiglitazone for 14 days dose-dependently decreased plasma glucose levels, ED(50) = 4.3 and 23 mg/kg/day, respectively, in male KK-A(y) mice. In female SD rats, repeated administration of 14i at 12.5-100 mg/kg/day for 28 days had no effect on the hematocrit value (Ht) and red blood cell count (RBC), while rosiglitazone significantly decreased them from 25 mg/kg/day. In conclusion, 14i showed about a fivefold stronger hypoglycemic effect and fourfold or more weaker hemodilution effect than rosiglitazone, indicating that 14i is 20-fold or more safer than rosiglitazone. Compound 14i is a promising candidate for an efficacious and safe anti-diabetic drug targeting PPAR gamma and PTP-1B. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.035
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 作用下， 生成 4-甲基-2-戊烯酰胺
  参考文献：
  名称：

  Bruylants; Minetti, Bulletin des Societes Chimiques Belges, 1931, vol. 40, p. 2

  摘要：

  DOI：

文献信息

• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2016191172A1

  公开（公告）日：2016-12-01

  Compounds of formula (I) that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公式(I)的化合物是成纤维细胞生长因子抑制剂（FGFR），因此可用于治疗可通过抑制FGFR治疗的疾病。还披露了包含此类化合物的药物组合物以及制备此类化合物的过程。
• OXAZOLIDINONE DERIVATIVE HAVING FUSED RING
  申请人：Katoh Issei

  公开号：US20110098471A1

  公开（公告）日：2011-04-28

  The present invention provides a novel antimicrobial drug comprising an oxazolidinone derivative of the formula (I): or a pharmaceutically acceptable salt or solvate thereof; wherein ring A is ring B is a benzene ring optionally substituted with lower alkyl; ring C is an optionally substituted six-membered heterocycle containing at least one nitrogen atom and one to three double bond(s) in the ling wherein the atom at the point of attachment to ring B is a carbon atom; ring D is an optionally substituted five-membered ring containing one or two double bond(s) in the ring; A 1 and A 2 are independently nitrogen or carbon; m is 0 or 1; R represents H, —NHC(═O)R A , —NHC(═S)R A , —NH-het 1 , —O-het 1 , —S-het 1 , —S(═O)-het 1 , —S(═O) 2 -het 1 , het 2 , —CONHR A , —OH, lower alkyl, lower alkoxy or lower alkenyl; and het 1 and het 2 are independently a heterocyclic group; with the proviso that the fused ring C-D is not

  本发明提供了一种新型抗菌药物，包括式(I)的噁唑烷酮衍生物： 或其药学上可接受的盐或溶剂；其中环A是 环B是一个苯环，可选择地取代为较低的烷基；环C是一个可选择地取代的含有至少一个氮原子和一个到三个双键的六元杂环，在连接到环B的点的原子是一个碳原子；环D是一个可选择地取代的含有一个或两个双键的五元环；A 1 和A 2 独立地是氮或碳；m为0或1；R代表H，—NHC(═O)R A ，—NHC(═S)R A ，—NH-het 1 ，—O-het 1 ，—S-het 1 ，—S(═O)-het 1 ，—S(═O) 2 -het 1 ，het 2 ，—CONHR A ，—OH，较低的烷基，较低的烷氧基或较低的烯基；和het 1 和het 2 独立地是一个杂环基团；但附带条件是融合的环C-D不是
• Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety
  作者：Xiaohan Hu、Sheng Tang、Feiyi Yang、Pengwu Zheng、Shan Xu、Qingshan Pan、Wufu Zhu

  DOI：10.3390/molecules26103041

  日期：——

  Two series of olmutinib derivatives containing an acrylamide moiety were designed and synthesized, and their IC50 values against cancer cell lines (A549, H1975, NCI-H460, LO2, and MCF-7) were evaluated. Most of the compounds exhibited moderate cytotoxic activity against the five cancer cell lines. The most promising compound, H10, showed not only excellent activity against EGFR kinase but also positive

  设计并合成了两个系列的含有丙烯酰胺部分的olmutinib衍生物，并评估了它们对癌细胞系的IC 50值（A549，H1975，NCI-H460，LO2和MCF-7）。大多数化合物对五种癌细胞系表现出中等的细胞毒活性。最有希望的化合物H10不仅显示出对EGFR激酶的出色活性，而且还显示出对PI3K激酶的积极生物学活性。结构-活性关系（SAR）表明，引入具有较小空间结构的二甲胺支架更有利于抗肿瘤活性。另外，不同丙烯酰胺侧链的取代对化合物的活性有不同的影响。通常，化合物H7H10和H10被证实是有希望的抗肿瘤药物。
• Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations
  作者：Zhen Xiao、Zhihui Zhou、Cilong Chu、Qian Zhang、Lingjia Zhou、Zunhua Yang、Xin Li、Liying Yu、Pengwu Zheng、Shan Xu、Wufu Zhu

  DOI：10.1016/j.ejmech.2020.112511

  日期：2020.10

  Five series of novel thiophene-pyrimidine derivatives (9a-h, 10a-f, 11a-f, 12a-f, 13a-f) have been synthesized and tested for their anti-proliferative activity against several cancer cell lines in which EGF is highly expressed. Most of the target compounds showed excellent activity against one or more cancer cell lines. The most promising compound 13a, of which IC50 values on of cell lines A549 and

  已经合成了五种系列的新型噻吩-嘧啶衍生物（9a-h，10a-f，11a-f，12a-f，13a-f），并测试了其对几种癌细胞株的抗增殖活性，其中EGF含量很高。表达。大多数目标化合物对一种或多种癌细胞系均表现出优异的活性。最有前途的化合物13a在细胞系A549和A431上的IC 50值（4.34±0.60μM和3.79±0.57μM）与先导化合物Olmutinib相似，显示出对EGFR T790M和EGFR T790M / L858R的强活性和选择性。人类正常肝癌细胞株LO2的抑制数据表明，大多数目标化合物对正常细胞的毒性较小，并对癌细胞具有选择性抑制作用。此外，分析了结构-活性关系，并研究了13a诱导的细胞凋亡机制。结果表明，化合物13a以剂量依赖性方式诱导A431癌细胞的晚期凋亡。
• SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR
  申请人：Commons Thomas Joseph

  公开号：US20090197878A1

  公开（公告）日：2009-08-06

  Compounds of formula (I), or pharmaceutically acceptable salts thereof, are provided, wherein R 1 -R 6 and X are defined herein. Also provided are methods of preparing the compounds of formula (I), pharmaceutical compositions and kits containing a compound of formula (I), as are methods of treating endometriosis, hormone-dependent carcinomas, leiomyoma, fibroids, dysfunctional bleeding, polycystic ovary syndrome, and menopause related symptoms; methods of contraception; methods of providing hormone replacement therapy; methods of stimulating food intake; methods of synchronizing estrus; and methods of treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder by administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (I).

  提供式(I)的化合物，或其药学上可接受的盐，其中R1-R6和X在此处有定义。还提供了制备式(I)化合物的方法，含有式(I)化合物的药物组合物和试剂盒，以及治疗子宫内膜异位症、激素依赖性癌症、平滑肌瘤、子宫肌瘤、功能性出血、多囊卵巢综合征和与更年期相关症状的方法；避孕方法；提供激素替代疗法的方法；促进食欲的方法；同步发情的方法；以及通过向需要的哺乳动物施用式(I)化合物的药学有效量来治疗经前综合征和经前期情感障碍症状的方法。